Health
TG Therapeutics Announces Positive Topline Results from Phase 3 ENHANCE Trial
Phase 3 trial met its primary endpoint, demonstrating bioequivalent drug exposure between the currently approved BRIUMVI Day 1 and Day 15 initiation dosing and a new single infusion on Day 1 only Safety and tolerability of the consolidated first infusion were consistent with the established BRIUMVI safety profile Supplemental BLA filing targeted 2H-2026 NEW YORK, May 27, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced positive topline results from the Phase 3 ENHAN
About this update from Tg Therapeutics, Inc.
[{"type":"image","alt":"TG Therapeutics, Inc.","displaySize":"","headline":null,"caption":"TG Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":79,"url":"https://media.zenfs.com/en/globenewswire.com/cc1df9bb4678bf5c14f62e021fa1fad1"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/SDBygDD99LtQB0oJDC8xZg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExMQ--/https://media.zenfs.com/en/globenewswire.com/cc1df9bb4678bf5c14f62e021fa1fad1","width":300,"height":79},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/SDBygDD99LtQB0oJDC8xZg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExMQ--/https://media.zenfs.com/en/globenewswire.com/cc1df9bb4678bf5c14f62e021fa1fad1","width":300,"height":79}},"lazy":false},{"type":"text","content":"Phase 3 trial met its primary endpoint, demonstrating bioequivalent drug exposure between the currently approved BRIUMVI Day 1 and Day 15 initiation dosing and a new single infusion on Day 1 only","length":195,"tagName":"p"},{"type":"text","content":"Safety and tolerability of the consolidated first infusion were consistent with the established BRIUMVI safety profile","length":118,"tagName":"p"},{"type":"text","content":"Supplemental BLA filing targeted 2H-2026","length":40,"tagName":"p"},{"type":"text","content":"NEW YORK, May 27, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced positive topline results from the Phase 3 ENHANCE trial, a randomized, double-blind study evaluating a consolidated single infusion regimen for initiation of BRIUMVI® (ublituximab-xiiy) in adults with relapsing forms of multiple sclerosis (RMS). The trial met its primary endpoint, demonstrating bioequivalent drug exposure between the currently approved initiation dosing regimen of 150 mg on Day 1 and 450 mg on Day 15 and a consolidated single 600 mg infusion on Day 1, eliminating the need for a Day 15 infusion. Topline outcomes from the ENHANCE Phase 3 study are highlighted below, and full results are expected to be presented at an upcoming medical meeting.","length":762,"tagName":"p"},{"type":"text","content":"Michael S. Weiss, Chairman and Chief Executive Officer of TG Therapeutics, stated: “We are very pleased to share these positive results from our ENHANCE Phase 3 trial. By eliminating the need for a second infusion visit two weeks after treatment initiation, this streamlined dosing re...